āĻŽā§āĻĄāĻŋāĻā§āĻļāύ āĻĨā§āϰāĻžāĻĒāĻŋ āĻŽā§āϝāĻžāύā§āĻāĻŽā§āύā§āĻ (MTM) āĻā§āϝāĻžāϞā§-āĻŦā§āϏāĻĄ āĻŽā§āĻĄāĻŋāϏāĻŋāύ āĻĒā§āϰā§āĻā§āϰāĻžāĻŽāĻā§āϞāĻŋāϰ āĻāύā§āϝ āĻā§ āĻĄā§āĻāĻž āĻŦāĻž āϰāĻŋāĻĒā§āϰā§āĻāĻŋāĻ āϏāϰāĻŦāϰāĻžāĻš āĻāϰāϤ⧠āĻĒāĻžāϰā§?
āĻŽā§āĻĄāĻŋāĻā§āĻļāύ āĻĨā§āϰāĻžāĻĒāĻŋ āĻŽā§āϝāĻžāύā§āĻāĻŽā§āύā§āĻ (MTM) āĻĻā§āϰā§āϤ āĻā§āϝāĻžāϞā§-āĻŦā§āϏāĻĄ āĻŽā§āĻĄāĻŋāϏāĻŋāύ āĻĒā§āϰā§āĻā§āϰāĻžāĻŽāĻā§āϞāĻŋāϰ āĻāĻāĻāĻŋ āĻāĻŋāϤā§āϤāĻŋāĻĒā§āϰāϏā§āϤāϰ āĻšāϝāĻŧā§ āĻāĻ āĻā§āĨ¤ āĻā§āϝāĻŧāĻžāϰ āĻĒāĻžāĻĨā§āϰ āĻŽāϧā§āϝ⧠MTM āĻāĻā§āĻā§āϤ āĻāϰāĻžāϰ āĻŽāĻžāϧā§āϝāĻŽā§, āϏā§āĻŦāĻžāϏā§āĻĨā§āϝāϏā§āĻŦāĻž āĻĒā§āϰāĻĻāĻžāύāĻāĻžāϰā§, āĻĒā§āϝāĻŧāĻžāϰ āĻāĻŦāĻ āĻĢāĻžāϰā§āĻŽā§āϏāĻŋāĻā§āϞāĻŋ āĻāĻžāϰā§āϝāĻāϰ āĻĄā§āĻāĻž āϏāĻāĻā§āϰāĻš āĻāĻŦāĻ āϰāĻŋāĻĒā§āϰā§āĻ āĻāϰāϤ⧠āĻĒāĻžāϰ⧠āϝāĻž āϰā§āĻā§āϰ āĻĢāϞāĻžāĻĢāϞā§āϰ āĻāύā§āύāϤāĻŋ āĻāϰ⧠āĻāĻŦāĻ āĻā§āϝāĻžāϞā§-āĻĄā§āϰāĻŋāĻā§āύ āĻā§āϝāĻŧāĻžāϰ āϏāĻŽāϰā§āĻĨāύ āĻāϰā§āĨ¤.
āĻ āĻŽā§āĻāĻž āĻāĻāĻĄ āĻāĻŽā§āĻĒāĻžāĻāύā§āĻĄāĻŋāĻ āĻĢāĻžāϰā§āĻŽā§āϏāĻŋ, āĻāĻŽāĻžāĻĻā§āϰ āĻāύā§āύāϤ āĻāĻŽāĻāĻŋāĻāĻŽ āĻĒāϰāĻŋāώā§āĻŦāĻžāĻā§āϞāĻŋ āĻāώā§āϧā§āϰ āύāĻŋāϝāĻŧāĻŽ āĻŽā§āύ⧠āĻāϞāĻž āĻŦā§āĻĻā§āϧāĻŋ, āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻ āĻā§āϰāĻāϤāĻŋ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāĻŦāĻ āĻŽā§āϞā§āϝ-āĻāĻŋāϤā§āϤāĻŋāĻ āĻāώāϧ āĻĒā§āϰā§āĻā§āϰāĻžāĻŽāĻā§āϞāĻŋāϰ āĻāύā§āϝ āĻļāĻā§āϤāĻŋāĻļāĻžāϞ⧠āϰāĻŋāĻĒā§āϰā§āĻāĻŋāĻ āĻĒā§āϰāĻĻāĻžāύā§āϰ āĻāύā§āϝ āĻĄāĻŋāĻāĻžāĻāύ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤ āĻāĻ āĻĒā§āώā§āĻ āĻžāĻāĻŋ āĻāĻŽāĻāĻŋāĻāĻŽ āĻā§āĻĒāύā§āύ āĻāϰ⧠āĻāĻŽāύ āĻĄā§āĻāĻžāϰ āĻĒā§āϰāĻāĻžāϰ, āĻāĻāĻŋ āĻā§āĻāĻžāĻŦā§ āĻŽā§āϞā§āϝ-āĻāĻŋāϤā§āϤāĻŋāĻ āϝāϤā§āύā§āϰ āĻāĻĻā§āϝā§āĻāĻā§ āϏāĻŽāϰā§āĻĨāύ āĻāϰ⧠āĻāĻŦāĻ āĻŽā§āĻāĻž āĻāĻāĻĄ āĻā§āĻāĻžāĻŦā§ āĻāĻžāϰā§āϝāĻāϰā§, āĻĢāϞāĻžāĻĢāϞ-āĻāĻžāϞāĻŋāϤ āϰāĻŋāĻĒā§āϰā§āĻāĻŋāĻāϝāĻŧā§ āύā§āϤā§āϤā§āĻŦ āĻĻā§āϝāĻŧ āϤāĻž āĻ āύā§āĻŦā§āώāĻŖ āĻāϰā§āĨ¤.
- āϏāĻāĻā§āώāĻŋāĻĒā§āϤ āĻŦāĻŋāĻŦāϰāĻŖ: āĻāĻŽāĻāĻŋāĻāĻŽ (MTM) āĻāĻŦāĻ āĻā§āϝāĻžāϞā§-āĻŦā§āϏāĻĄ āĻŽā§āĻĄāĻŋāϏāĻŋāύ (Value-Based Medicine)
- MTM āĻĒā§āϰā§āĻā§āϰāĻžāĻŽāĻā§āϞāĻŋ āϝ⧠āĻŽā§āϞ āĻĄā§āĻāĻž āĻāĻĒāĻžāĻĻāĻžāύāĻā§āϞāĻŋ āϏāϰāĻŦāϰāĻžāĻš āĻāϰā§
- āĻŽā§āϞā§āϝ-āĻāĻŋāϤā§āϤāĻŋāĻ āĻāϰā§āĻŽāϏā§āĻāĻŋāϰ āĻāύā§āϝ āϰāĻŋāĻĒā§āϰā§āĻāĻŋāĻ āĻŽā§āĻā§āϰāĻŋāĻā§āϏ
- āĻŽā§āĻāĻž āĻāĻāĻĄā§āϰ āĻāĻŽāĻāĻŋāĻāĻŽ āĻĄā§āĻāĻž āĻ āϰāĻŋāĻĒā§āϰā§āĻāĻŋāĻ āϏāϞāĻŋāĻāĻļāύāϏ
- āĻā§āϏ āϏā§āĻāĻžāĻĄāĻŋ: āĻĄāĻžāϝāĻŧāĻžāĻŦā§āĻāĻŋāϏ āĻ ā§āϝāĻžāĻĄāĻšā§āϰā§āύā§āϏ āĻĒā§āϰā§āĻā§āϰāĻžāĻŽ
- āϤāĻĨā§āϝ āĻāĻŋāĻā§āϝā§āϝāĻŧāĻžāϞāĻžāĻāĻā§āĻļāύ āĻ āύāĻŽā§āύāĻž āĻĒā§āϰāϤāĻŋāĻŦā§āĻĻāύ
- āϏāĻžāϧāĻžāϰāĻŖ āĻāĻŋāĻā§āĻāĻžāϏā§āϝ
- āĻāĻŋāĻāĻžāĻŦā§ āĻļā§āϰ⧠āĻāϰāĻŦā§āύ
āϏāĻžāϰāϏāĻāĻā§āώā§āĻĒ: āĻāĻŽāĻāĻŋāĻāĻŽ āĻāĻŦāĻ āĻā§āϝāĻžāϞā§-āĻŦā§āϏāĻĄ āĻŽā§āĻĄāĻŋāϏāĻŋāύ
āĻāώā§āϧ āĻŦā§āϝāĻŦāϏā§āĻĨāĻžāĻĒāύāĻžÂ āĻŦā§āϝāĻā§āϤāĻŋāĻāϤāĻā§āϤ āĻā§āϞāĻŋāύāĻŋāĻāĻžāϞ āĻšāϏā§āϤāĻā§āώā§āĻĒā§āϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻāώā§āϧā§āϰ āϏāϰā§āĻŦā§āϤā§āϤāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ, āύāĻŋāϝāĻŧāĻŽ āĻŽā§āύ⧠āĻāώā§āϧ āϏā§āĻŦāύ āĻŦā§āĻĻā§āϧāĻŋ, āĻāĻŦāĻ āϰā§āĻā§āϰ āĻĢāϞāĻžāĻĢāϞ⧠āĻĒā§āϰāĻāĻžāĻŦ āĻĢā§āϞ⧠āĻāĻŽāύ āĻŦāĻžāϧāĻžāĻā§āϞāĻŋ āĻĻā§āϰ āĻāϰāĻžāĨ¤. āĻŽā§āϞā§āϝ-āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āĻĄāĻŋāϏāĻŋāĻ¨Â āĻāύā§āύāϤ āϰā§āĻā§āϰ āĻĢāϞāĻžāĻĢāϞ āĻ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝāϏā§āĻŦāĻžāϰ āĻāϰāĻ āĻšā§āϰāĻžāϏā§āϰ āĻāύā§āϝ āĻĒā§āϰāĻĻāĻžāύāĻāĻžāϰā§āĻĻā§āϰ āĻĒā§āϰāϏā§āĻā§āϤ āĻāϰā§, āĻĄā§āĻāĻž-āĻāĻžāϞāĻŋāϤ āĻāĻŽāĻāĻŋāĻāĻŽ-āĻā§ āĻāĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻāĻĒāĻžāĻĻāĻžāύ āĻāϰ⧠āϤā§āϞā§āĨ¤.
āĻāĻŽāĻāĻŋāĻāĻŽ āĻŽā§āϞā§āϝ-āĻāĻŋāϤā§āϤāĻŋāĻ āϝāϤā§āύ⧠āĻā§āĻāĻžāĻŦā§ āϏāĻšāĻžāϝāĻŧāϤāĻž āĻāϰā§:
MTM āĻĒā§āϰā§āĻā§āϰāĻžāĻŽāĻā§āϞāĻŋ āϝ⧠āĻŽā§āϞ āĻĄā§āĻāĻž āĻāĻĒāĻžāĻĻāĻžāύāĻā§āϞāĻŋ āϏāϰāĻŦāϰāĻžāĻš āĻāϰā§
MTM āĻĒā§āϰā§āĻā§āϰāĻžāĻŽāĻā§āϞāĻŋ āĻā§āϝāĻžāϞā§-āĻŦā§āϏāĻĄ āĻŽā§āĻĄāĻŋāϏāĻŋāύ āĻāĻĻā§āϝā§āĻā§āϰ āĻāύā§āϝ āĻ āĻĒāϰāĻŋāĻšāĻžāϰā§āϝ āĻĄā§āĻāĻž āĻĒāϝāĻŧā§āύā§āĻā§āϰ āĻŦāĻŋāĻāĻŋāύā§āύ āϏāĻāĻā§āϰāĻš āĻ āĻĒā§āϰāϤāĻŋāĻŦā§āĻĻāύ āĻāϰā§āĨ¤ āύāĻŋāĻā§ āĻŽā§āϞ MTM āĻĄā§āĻāĻž āĻāĻĒāĻžāĻĻāĻžāύāĻā§āϞāĻŋāϰ āĻāĻāĻāĻŋ āϏāĻžāϰāϏāĻāĻā§āώā§āĻĒ āĻā§āĻŦāĻŋāϞ āĻĻā§āĻāϝāĻŧāĻž āĻšāϞā§:
| āϤāĻĨā§āϝ āĻāĻĒāĻžāĻĻāĻžāύ | āĻŦāĻŋāĻŦāϰāĻŖ | āĻāĻŋāĻŦāĻŋāĻĒāĻŋ* āĻāϰ āĻāύā§āϝ āĻŽāĻžāύ |
|---|---|---|
| āĻāώā§āϧ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āϏā§āĻŦāύ | % āĻĻāĻŋāύā§āϰ āĻāύā§āϝ āϰā§āĻā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāώā§āϧ āĻā§āϰāĻšāĻŖ (PDC) | āĻāĻā§āĻ (āϏāĻŋāĻāĻŽāĻāϏ, āĻĒā§āϰāĻĻā§āϝāĻŧāĻāĻžāϰā§) |
| āĻĨā§āϰāĻžāĻĒāĻŋāϤ⧠āĻĢāĻžāĻāĻ | āĻāώā§āϧā§āϰ āĻāĻāĻžāϰā§āĻ āĻāĻžāĻĄāĻŧāĻž āĻĻāĻŋāύ | āĻāĻā§āĻ |
| āĻāώā§āϧ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻĢāϞāĻžāĻĢāϞ | āϏā§āĻĒāĻžāϰāĻŋāĻļ, āĻĨā§āϰāĻžāĻĒāĻŋāϰ āϏāĻžāĻŽāĻā§āĻāϏā§āϝ, āĻšāϏā§āϤāĻā§āώā§āĻĒ | āĻŽāĻžāĻāĻžāϰāĻŋ |
| āϰā§āĻā§ āĻļāĻŋāĻā§āώāĻž/āĻĒā§āϰāĻļāĻŋāĻā§āώāĻŖ | āĻĒāϰāĻžāĻŽāϰā§āĻļā§āϰ āύāĻĨāĻŋ, āϰā§āĻ āĻŦāĻŋāώāϝāĻŧāĻ āĻļāĻŋāĻā§āώāĻž | āĻŽāĻžāĻāĻžāϰāĻŋ |
| āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϝāĻžāϰāĻžāĻŽāĻŋāĻāĻžāϰ | āĻā§§āϏāĻŋ (āĻĄāĻžāϝāĻŧāĻžāĻŦā§āĻāĻŋāϏ), āϰāĻā§āϤāĻāĻžāĻĒ, āĻāϞāĻĄāĻŋāĻāϞ, āĻāϤā§āϝāĻžāĻĻāĻŋ. | āĻāĻā§āĻ |
| āĻāϰāĻā§āϰ āϤāĻĨā§āϝ | āĻĒā§āϞā§āϝāĻžāύ-āĻĒā§āĻāĻĄ, āϰā§āĻā§-āĻĒā§āĻāĻĄ, āĻā§-āĻĒā§āĻŽā§āύā§āĻ | āĻŽāĻžāĻāĻžāϰāĻŋ |
| āĻĒā§āϰāϤāĻŋāĻā§āϞ āĻāĻāύāĻž/āĻĒāĻžāϰā§āĻļā§āĻŦ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋāϝāĻŧāĻž | āĻā§āϰā§āϝāĻžāĻāĻŋāĻ āĻāĻŦāĻ āϰāĻŋāĻĒā§āϰā§āĻāĻŋāĻ | āĻāĻā§āĻ |
| āϰā§āĻā§āϰ āϏāύā§āϤā§āώā§āĻāĻŋ | āĻāϰāĻŋāĻĒā§āϰ āϏā§āĻā§āϰ, āĻā§āĻŖāĻāϤ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋāϝāĻŧāĻž | āĻŽāĻžāĻāĻžāϰāĻŋ |
| āĻĒā§āϰāĻĻāĻžāύāĻāĻžāϰā§āϰ āϝā§āĻāĻžāϝā§āĻ | āĻšāϏā§āϤāĻā§āώā§āĻĒ, āĻĢāϞāĻžāĻĢāϞ āĻĒā§āϰāϤāĻŋāĻŦā§āĻĻāύ | āĻāĻā§āĻ |
*āĻāĻŋāĻŦāĻŋāĻĒāĻŋ = āĻā§āϝāĻžāϞā§-āĻŦā§āϏāĻĄ āĻĒā§āϰā§āĻā§āϰāĻžāĻŽ
āĻā§āϝāĻžāϞā§-āĻŦā§āϏāĻĄ āĻĒā§āϰā§āĻā§āϰāĻžāĻŽā§āϰ āĻāύā§āϝ āĻŽā§āĻā§āϰāĻŋāĻā§āϏ āϰāĻŋāĻĒā§āϰā§āĻ
āϏāĻžāϧāĻžāϰāĻŖ āĻāĻŽāĻāĻŋāĻāĻŽ āĻŽā§āĻā§āϰāĻŋāĻā§āϏ āĻā§āϰā§āϝāĻžāĻ āĻ āϰāĻŋāĻĒā§āϰā§āĻ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§:
- āĻĻāĻŋāύāĻā§āϞāĻŋāϰ āĻ āύā§āĻĒāĻžāϤ (PDC): āϰā§āĻā§ āĻāϤ āύāĻŋāϝāĻŧāĻŽāĻŋāϤāĻāĻžāĻŦā§ āϤāĻžāĻĻā§āϰ āĻāώā§āϧ āĻā§āϰāĻšāĻŖ āĻāϰ⧠āϤāĻžāϰ āĻļāϤāĻžāĻāĻļāĨ¤.
- āĻĨā§āϰāĻžāĻĒāĻŋāϤ⧠āĻĢāĻžāĻāĻ (āĻāĻŋāĻāĻāĻāĻŋ): āϰā§āĻā§ āĻĨā§āϰāĻžāĻĒāĻŋāϰ āĻāĻāϤāĻžāϰ āĻŦāĻžāĻāϰ⧠āĻāĻŋāϞā§āύ āĻāĻŽāύ āĻĻāĻŋāύā§āϰ āϏāĻāĻā§āϝāĻžāĨ¤.
- āĻā§āϞāĻŋāύāĻŋāĻāĻžāϞ āĻĢāϞāĻžāĻĢāϞ: āϞā§āϝāĻžāĻŦ āĻŽāĻžāύā§āϰ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ (A1c, BP), āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ⧠āĻāϰā§āϤāĻŋ, āĻāϰā§āϰāĻŋ āĻŦāĻŋāĻāĻžāĻā§ āĻĒā§āϰāĻŦā§āĻļāĨ¤.
- āĻāϰāĻ āύāĻŋāϰā§āϧāĻžāϰāĻ āĻĢāĻžāϰā§āĻŽā§āϏāĻŋ āĻŦā§āϝāϝāĻŧ, āĻāĻŋāĻāĻŋā§āϏāĻž āĻŦā§āϝāϝāĻŧ, āĻāϰāĻ āĻāĻĄāĻŧāĻžāύā§āĨ¤.
- āϰā§āĻā§āϰ āϏāĻŽā§āĻĒā§āĻā§āϤāϤāĻžÂ āĻĒā§āϰāĻļāĻŋāĻā§āώāĻŖā§ āĻ āĻāĻļāĻā§āϰāĻšāĻŖ, āĻĢāϞā§-āĻāĻĒ āĻ ā§āϝāĻžāĻĒāϝāĻŧā§āύā§āĻāĻŽā§āύā§āĻāĨ¤.
- āĻšāϏā§āϤāĻā§āώā§āĻĒ āĻā§āϰāĻšāĻŖ āĻšāĻžāĻ°Â āĻĒā§āϰāĻĻāĻžāύāĻāĻžāϰā§āϰāĻž MTM āϏā§āĻĒāĻžāϰāĻŋāĻļāĻā§āϞāĻŋāϰ % āĻā§āϰāĻšāĻŖ āĻāϰā§āĻā§āĨ¤.
- āϏā§āĻŦāĻžāϏā§āĻĨā§āϝ āĻŦā§āώāĻŽā§āϝ āĻšā§āϰāĻžāĻ¸Â āϞāĻŋāĻā§āĻ, āĻŦāϝāĻŧāϏ āĻŦāĻž āĻ āĻŦāϏā§āĻĨāĻžāϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āĻĢāϞāĻžāĻĢāϞāĨ¤.
āĻŽā§āĻāĻž āĻāĻāĻĄā§āϰ āĻāĻŽāĻāĻŋāĻāĻŽ āĻĄā§āĻāĻž āĻ āϰāĻŋāĻĒā§āϰā§āĻāĻŋāĻ āϏāϞāĻŋāĻāĻļāύāϏ
āĻŽā§āĻāĻž āĻāĻāĻĄ āĻāĻŽā§āĻĒāĻžāĻāύā§āĻĄāĻŋāĻ āĻĢāĻžāϰā§āĻŽā§āϏāĻŋāϤ⧠āĻāĻŽāϰāĻž:
- āĻŽāĻŋāĻļā§āϰāĻŖ (compounding) āĻāϰāĻžāϰ āĻāĻā§, āĻāĻŽāϰāĻž āĻāώā§āϧā§āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž (Drug Utilization Review) āĻāϰāĻŋ â āϰā§āĻā§āϰ āĻŦāϰā§āϤāĻŽāĻžāύ⧠āύā§āĻāϝāĻŧāĻž āϏāĻŽāϏā§āϤ āĻāώā§āϧ, āĻāĻŽāύāĻāĻŋ āĻ āύā§āϝ āĻĄāĻžāĻā§āϤāĻžāϰāĻĻā§āϰ āĻĻā§āĻāϝāĻŧāĻž āĻāώā§āϧāĻā§āϞāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž āĻāϰāĻŋ, āϝāĻžāϤ⧠āĻāώā§āϧā§āϰ āϏāĻā§āĻā§ āĻā§āώāϤāĻŋāĻāϰ āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋāϝāĻŧāĻž āĻāĻĄāĻŧāĻžāύ⧠āϝāĻžāϝāĻŧāĨ¤
- āĻĢā§āύ⧠āϰā§āĻā§āĻĻā§āϰ āĻāώā§āϧā§āϰ āϏāĻ āĻŋāĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āϏāĻŽā§āĻĒāϰā§āĻā§ āĻāĻžāύāĻžāύ āĻāĻŦāĻ āĻāĻāĻāĻŋāĻāĻŦā§ āĻāĻŋāĻĄāĻŋāĻ āύāĻŋāϰā§āĻĻā§āĻļāĻŋāĻāĻž āĻĒā§āϰāĻĻāĻžāύ āĻāϰā§āύ
- āϰā§āĻā§āĻĻā§āϰ āĻāώā§āϧā§āϰ āύāĻŋāϝāĻŧāĻŽ āĻŽā§āύ⧠āĻāϞāĻž āĻāĻŦāĻ āĻā§āϞāĻŋāύāĻŋāĻāĻžāϞ āĻĢāϞāĻžāĻĢāϞāĻā§āϞāĻŋ āϰāĻŋāϝāĻŧā§āϞ-āĻāĻžāĻāĻŽā§ āĻā§āϰā§āϝāĻžāĻ āĻāϰā§āύāĨ¤.
- āϝāĻžāϰāĻž āĻāώā§āϧ āĻā§āϰāĻšāĻŖā§ āĻ āύā§āĻšāĻž āĻŦāĻž āĻāĻāĻŋāϞāϤāĻžāϰ āĻā§āĻāĻāĻŋāϤ⧠āĻāĻā§ āϤāĻžāĻĻā§āϰ āĻāĻŋāĻšā§āύāĻŋāϤ āĻāϰā§āύāĨ¤.
- āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻ āĻā§āϰāĻāϤāĻŋ āĻāĻŦāĻ āĻĢāϞāĻžāĻĢāϞ āϏāϰāĻžāϏāϰāĻŋ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝāϏā§āĻŦāĻž āĻĒā§āϰāĻĻāĻžāύāĻāĻžāϰā§āĻĻā§āϰ āĻāĻžāĻā§ āϰāĻŋāĻĒā§āϰā§āĻ āĻāϰā§āύ āϝāĻžāϤ⧠āĻĒā§āϰāϝāĻŧā§āĻāύ⧠āĻĨā§āϰāĻžāĻĒāĻŋ āϏāĻžāĻŽāĻā§āĻāϏā§āϝ āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤.
- āύāĻŋāϰāĻŦāĻā§āĻāĻŋāύā§āύ āĻĒāϰāĻŋāĻāϰā§āϝāĻžāϰ āĻāύā§āύāϤāĻŋāϰ āĻāύā§āϝ āĻĒā§āϰāĻĻāĻžāύāĻāĻžāϰā§āĻĻā§āϰ āϏāĻžāĻĨā§ āĻā§āϞā§āĻāĻĄ-āϞā§āĻĒ āϝā§āĻāĻžāϝā§āĻā§āϰ āϏāĻŽāϰā§āĻĨāύ āĻāϰā§āύāĨ¤.
āĻŽā§āĻāĻž āĻāĻāĻĄ āĻāĻŽāĻāĻŋāĻāĻŽ āϰāĻŋāĻĒā§āϰā§āĻāĻŋāĻ āĻāϝāĻŧāĻžāϰā§āĻāĻĢā§āϞā§
āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āĻāĻŦā§āώāĻŖāĻž (āϤāĻĨā§āϝāϏā§āϤā§āϰ āĻĻā§āĻā§āύ) āĻ āύā§āϝāĻžāϝāĻŧā§, āĻŽā§āϞā§āϝ-āĻāĻŋāϤā§āϤāĻŋāĻ āĻŦā§āĻŽāĻž āĻāĻŦāĻ āĻāĻŽāĻāĻŋāĻāĻŽ āĻĒā§āϰā§āĻā§āϰāĻžāĻŽā§āϰ āϏāĻŽāύā§āĻŦāĻŋāϤ āϰā§āĻĒ āύāĻŋāĻŽā§āύāϞāĻŋāĻāĻŋāϤāĻā§āϞāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§:
- PDC āĻšāĻžāϰ āĻŦā§āĻĻā§āϧāĻŋ āĻāϰā§āύ (āϝā§āĻŽāύ, āĻ -āĻ āύā§āĻāϤ āϰā§āĻā§āĻĻā§āϰ āĻā§āώā§āϤā§āϰ⧠84.7% āĻĨā§āĻā§ 93.1%-āĻ)
- āĻāώāϧ āĻāĻžāĻĄāĻŧāĻž āĻĻāĻŋāύā§āϰ āϏāĻāĻā§āϝāĻž āĻāϞā§āϞā§āĻāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻāĻŽāĻžāύ⧠(ā§§ā§Ļ.ā§Ŧ⧝ āĻĻāĻŋāύ āĻĒāϰā§āϝāύā§āϤ)
- āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻŋāĻā§ āĻā§āώā§āĻ ā§āϰ (āĻŦāĻŋāĻļā§āώāϤ āĻŽāĻšāĻŋāϞāĻž āϰā§āĻā§āĻĻā§āϰ) āĻĢāϞāĻžāĻĢāϞ āĻāύā§āύāϤ āĻāϰāĻž
- āĻĢāĻžāϰā§āĻŽāĻžāϏāĻŋ āĻāĻŦāĻ āϏāĻžāĻŽāĻā§āϰāĻŋāĻ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝāϏā§āĻŦāĻžāϰ āĻŦā§āϝāϝāĻŧā§āϰ āĻāύā§āϝ āĻāϰāĻ āĻŦā§āĻā§āĻāĻŽāĻžāϰā§āĻ
āĻŽā§āĻāĻž āĻāĻāĻĄ āĻāĻĻāĻžāĻšāϰāĻŖ:
āĻāĻŽāĻžāĻĻā§āϰ āĻŦā§āϝāĻĨāĻž āĻŦā§āϝāĻŦāϏā§āĻĨāĻžāĻĒāύāĻž MTM āĻĒā§āϰā§āĻā§āϰāĻžāĻŽā§ āĻ āĻāĻļāĻā§āϰāĻšāĻŖāĻāĻžāϰ⧠āϰā§āĻā§āĻĻā§āϰ āĻāĻāĻāĻŋ āĻāϰāĻŋāĻĒā§āϰ āĻĢāϞāĻžāĻĢāϞ āĻ āύā§āϝāĻžāϝāĻŧā§, āϝāĻžāϰ āĻŽāϧā§āϝ⧠āĻĄāĻžāϝāĻŧāĻžāĻŦā§āĻāĻŋāĻ āύāĻŋāĻāϰā§āĻĒā§āϝāĻžāĻĨāĻŋ, āĻāϰā§āĻĨā§āϰāĻžāĻāĻāĻŋāϏ āĻāĻŦāĻ āϏāύā§āϧāĻŋ āĻ āĻĒā§āĻļā§āϰ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāϰ āϤāĻĨā§āϝ āĻ āύā§āϤāϰā§āĻā§āĻā§āϤ, ā§Žā§Ē.⧍⧧% āϰā§āĻā§ āĻŦā§āϝāĻĨāĻžāϰ āĻŽāĻžāϤā§āϰāĻž āĻšā§āϰāĻžāϏā§āϰ āĻāĻĨāĻž āĻāĻžāύāĻŋāϝāĻŧā§āĻā§āύāĨ¤.
āĻāĻĻāĻžāĻšāϰāĻŖ āϏāĻžāϰāĻŖā§: āĻāĻŽāĻāĻŋāĻāĻŽ-āĻāϰ āĻāĻā§ āĻ āĻĒāϰ⧠āĻ āύā§āĻŦāϰā§āϤāĻŋāϤāĻž āĻŽā§āĻā§āϰāĻŋāĻā§āϏ
| āĻŽā§āĻā§āϰāĻŋāĻ | āĻĒā§āϰāĻŋ-āĻāĻŽāĻāĻŋāĻāĻŽ āĻšāϏā§āϤāĻā§āώā§āĻĒ | āĻĒā§āϏā§āĻ-āĻāĻŽāĻāĻŋāĻāĻŽ āĻšāϏā§āϤāĻā§āώā§āĻĒ |
|---|---|---|
| āĻĒāĻŋāĻĄāĻŋāϏāĻŋ (ā§§āĻāĻŋāĻĒāĻŋā§ŠāĻāĻŋ) | 84.7 | 93.1 |
| āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĢāĻžāĻāĻ (āĻĻāĻŋāύ) | 15.2 | 4.5 |
āύāĻŽā§āύāĻž āϏāϰāĻŦāϰāĻžāĻšāĻāĻžāϰ⧠āĻĒā§āϰāϤāĻŋāĻŦā§āĻĻāύ āĻŦāĻŋāĻāĻžāĻāĻā§āϞāĻŋ:
- āϰā§āĻā§ āĻā§āώā§āĻ ā§ āϏāĻžāϰāĻžāĻāĻļ
- āĻāύā§āĻāϤā§āϝ āĻ āĻā§āϝāĻžāĻĒ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ
- āĻšāϏā§āϤāĻā§āώā§āĻĒā§āϰ āĻĢāϞāĻžāĻĢāϞ āĻāĻŦāĻ āĻĒāϰāĻŦāϰā§āϤ⧠āĻĒāĻĻāĻā§āώā§āĻĒ
- Recommendations for further care
āϏāĻžāϧāĻžāϰāĻŖ āĻāĻŋāĻā§āĻāĻžāϏā§āϝ
Q: How can Mega Aidâs MTM data be integrated into existing value-based care workflows?
A: Mega Aid structures MTM data so it can align with existing provider, payer, and health system workflows. Reports are designed to support clinical reviews, quality meetings, and value-based performance evaluations by summarizing therapy effectiveness, adherence trends, and intervention outcomes in a format that complements EHR reviews, care coordination discussions, and payer reporting requirements.
Q: Does Mega Aidâs MTM support longitudinal tracking of patient outcomes over time?
A: Yes. Mega Aidâs MTM program emphasizes longitudinal monitoring, allowing providers and care teams to evaluate trends in adherence, symptom improvement, and treatment response over time. This longitudinal view is especially valuable for chronic conditions and value-based programs that reward sustained improvements rather than short-term results.
Q: How does Mega Aidâs MTM reporting support clinical decision-making beyond adherence metrics?
A: In addition to adherence data, Mega Aidâs MTM reporting highlights therapy effectiveness, patient-reported outcomes, tolerance issues, and opportunities for formulation or dosing adjustments. This enables providers to make informed clinical decisions, refine treatment plans, and improve outcomes without relying solely on claims-based or refill-level data.
Q: Is Mega Aidâs MTM reporting suitable for specialty, compounded, or non-standard therapies?
A: Yes. Mega Aidâs MTM program is specifically designed to support compounded and customized therapies that are often excluded from traditional reporting models. By tracking real-world use, patient education effectiveness, and treatment response, Mega Aid provides visibility into therapies that may not be fully captured by standard pharmacy benefit or claims systems.
Q:Â How does Mega Aid ensure MTM data supports quality, compliance, and audit readiness?
A:Â Mega Aid operates within PCAB accreditation standards and USP 795/800 compliance, with structured documentation and consistent follow-up processes. MTM interactions, interventions, and outcome tracking are documented to support quality oversight, internal audits, and external reviews tied to value-based or performance-driven care models.
Mega Aid is a PCAB-accredited, USP 795/800 compliant pharmacy specializing in personalized MTM and compounding solutions, serving the greater New York area and New Jersey. Our mission is to optimize outcomes and support value-based healthcare through innovation, collaboration, and robust reporting.
